Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) has shared an announcement.
Orexo AB has announced that it will release its Q3 2025 Interim Report on October 23, followed by a presentation featuring updates on its partnership with BARDA and the OX390 project. This event will include insights from the CEO, CFO, and Chief Medical Officer, and will be accessible via live audiocast and teleconference, highlighting the company’s ongoing strategic developments and stakeholder engagement.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies to address significant medical needs. The company is known for providing innovative treatment solutions for opioid use disorder in the US and collaborates with leading partners to develop products for other therapeutic areas globally. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
Average Trading Volume: 59,965
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.43B
See more data about ORX stock on TipRanks’ Stock Analysis page.